Shuxian Qu,Zhendong Zheng,Zhaozhe Liu,Jianing Qiu,Xiaodong Xie. The use of aprepitant and palonosetron in preventing chemotherapy-related nausea and vomiting inlung cancer patients. Oncol Transl Med, 2017, 3: 108-110.
The use of aprepitant and palonosetron in preventing chemotherapy-related nausea and vomiting inlung cancer patients
Received:November 28, 2016  Revised:May 26, 2017
View Full Text  View/Add Comment  Download reader
KeyWord:aprepitant; palonosetron hydrochloride capsule; cisplatinum; tropisetron
Author NameAffiliationE-mail
Shuxian Qu Department of Oncology, The General Hospital of Shenyang Military Region, Shenyang 110840, China qushuxian2010@163.com 
Zhendong Zheng Department of Oncology, The General Hospital of Shenyang Military Region, Shenyang 110840, China  
Zhaozhe Liu Department of Oncology, The General Hospital of Shenyang Military Region, Shenyang 110840, China  
Jianing Qiu Department of Oncology, The General Hospital of Shenyang Military Region, Shenyang 110840, China  
Xiaodong Xie Department of Oncology, The General Hospital of Shenyang Military Region, Shenyang 110840, China doctor_xxd@163.com 
Hits: 5443
Download times: 6253
Abstract:
      Objective?The aim of this study was to explore the clinical efficacy and toxicity of a combination aprepitant and palonosetron hydrochloride therapy in preventing chemotherapy-induced nausea and vomiting associated with a cisplatinum-based regimen in patients with lung cancer. Methods?Sixty-eight patients with lung cancer were randomly assigned to receive either aprepitant plus palonosetron hydrochloride (group A, n = 38) or tropisetron (group B, n = 30). Acute (0–24 h) and delayed (2–5 d) emetic episodes, nausea, vomiting, constipation, and dizziness were compared between the two groups in the five days following cisplatinum-based chemotherapy. Results?Group A had a higher complete control rate for both acute and delayed emetic episodes than Group B (36.8% vs. 13.3% and 31.6% vs. 13.3%, respectively; P < 0.05 for both). There was no significant difference in the constipation rate between the two groups. Conclusion?Aprepitant combined with palonosetron hydrochloride is active and well tolerated in both acute and delayed emetic episodes in patients with lung cancer treated by a cisplatinum-based regimen.
Close